BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1638551)

  • 21. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
    Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
    Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosis.
    Metelitsa LS; Gillies SD; Super M; Shimada H; Reynolds CP; Seeger RC
    Blood; 2002 Jun; 99(11):4166-73. PubMed ID: 12010822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon gamma.
    Blottiere HM; Douillard JY; Koprowski H; Steplewski Z
    Cancer Immunol Immunother; 1990; 32(1):29-37. PubMed ID: 2126982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
    Qi CF; Nieroda C; De Filippi R; Greiner JW; Correale P; Schlom J; Tsang KY
    Immunol Lett; 1995; 47(1-2):15-24. PubMed ID: 8537095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokinine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes.
    Ottonello L; Morone P; Dapino P; Dallegri F
    Blood; 1996 Jun; 87(12):5171-8. PubMed ID: 8652830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
    Tsang KY; Finch MD; Primus FJ; Schlom J
    Cancer Immunol Immunother; 1991; 34(1):9-16. PubMed ID: 1836975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study.
    Tsitsilonis OE; Tsavaris NB; Kosmas C; Gouveris P; Papalambros E
    J Chemother; 2003 Aug; 15(4):387-93. PubMed ID: 12962368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF.
    Bianchi AC; Heslop HE; Veys P; Macey M; Holland M; Prentice HG; Brenner MK
    Br J Haematol; 1989 Dec; 73(4):468-74. PubMed ID: 2692692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
    Wersäll P; Masucci G; Mellstedt H
    Cancer Immunol Immunother; 1991; 33(1):45-9. PubMed ID: 2021957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.
    Liljefors M; Nilsson B; Hjelm Skog AL; Ragnhammar P; Mellstedt H; Frödin JE
    Int J Cancer; 2003 Jul; 105(5):717-23. PubMed ID: 12740924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.
    Wadhwa M; Bird C; Fagerberg J; Gaines-Das R; Ragnhammar P; Mellstedt H; Thorpe R
    Clin Exp Immunol; 1996 May; 104(2):351-8. PubMed ID: 8625532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
    Batova A; Kamps A; Gillies SD; Reisfeld RA; Yu AL
    Clin Cancer Res; 1999 Dec; 5(12):4259-63. PubMed ID: 10632368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulocyte-macrophage colony stimulating factor in autologous bone marrow transplantation: augmentation of graft versus tumor effect via antibody dependent cellular cytotoxicity.
    Charak BS; Sadowski RM; Mazumder A
    Leuk Lymphoma; 1993 Apr; 9(6):453-7. PubMed ID: 8339051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulocyte- and granulocyte-macrophage colony-stimulating factors enhance neutrophil cytotoxicity toward HIV-infected cells.
    Baldwin GC; Fuller ND; Roberts RL; Ho DD; Golde DW
    Blood; 1989 Oct; 74(5):1673-7. PubMed ID: 2477084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity.
    Young DA; Lowe LD; Clark SC
    J Immunol; 1990 Jul; 145(2):607-15. PubMed ID: 2142182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.
    Kushner BH; Cheung NK
    Blood; 1989 May; 73(7):1936-41. PubMed ID: 2653466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.